Mallika Singh

Mallika Singh

Company: Revolution Medicine

Job title: Vice President, Translational Research

Seminars:

Panel Discussion: Revealing Signaling Vulnerabilities: Reviewing Emerging Targets for RAS Mutated Cancers 1:30 pm

As the landscape of approaches targeting RAS mutated cancers continues to grow, there are a whole host of investigational inhibitors focused on targeting the RAS signaling pathway and the high value targets which exist within. Now more than ever, it is critical to understand the regulatory mechanisms downstream and upstream of RAS and consider the…Read more

day: Day One

Mutant-Selective Inhibitors of RAS(ON) Beyond KRASG12C 9:00 am

Discovery of Potent, Selective, Covalent, Tricomplex Inhibitors of KRASG12D(ON) and KRASG13C(ON)Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.